Figure 1: Effects of different doses of curcumin on LPS-mediated TNF-α secretion by RAW264.7 cells. Values represent a mean of three independent experiments. *Significant difference between control and experimental group at P < 0.05 level |
Figure 2: Evaluation of serum IL-10 levels after curcumin treatment in LPS-induced endotoxaemia. Values represent a mean of three independent experiments. *Significant difference between control and experimental group at P < 0.05 level |
Figure 3: Evaluation of serum IFN-g levels after curcumin treatment in LPS-induced endotoxaemia. Values represent a mean of three independent experiments. *Significant difference between control and experimental group at P < 0.05 level |
Figure 4: Evaluation of serum IL-4 levels after curcumin treatment in LPS-induced endotoxaemia. Values represent a mean of three independent experiments. *Significant difference between control and experimental group at P < 0.05 level |
Group |
Absolute weight (g) |
Relative weight (%) |
||
---|---|---|---|---|
Intact ear |
Induced ear |
Intact ear |
Induced ear |
|
Control |
0.132 ± 0.012 |
0.182 ± 0.031 |
0.461 ± 0.051 |
0.617 ± 0.111 |
Sample #1 |
0.121 ± 0.008 |
0.141 ± 0.015*,** |
0.444 ± 0.043 |
0.501 ± 0.067*,** |
Sample #2 |
0.128 ± 0.015 |
0.175 ± 0.023* |
0.460 ± 0.051 |
0.602 ± 0.098* |
Sample #3 |
0.133 ± 0.011 |
0.161 ± 0.043*,** |
0.464 ± 0.045 |
0.555 ± 0.089* |
Sample #4 |
0.135 ± 0.014 |
0.171 ± 0.026* |
0.461 ± 0.039 |
0.599 ± 0.102* |
Sample #5 |
0.127 ± 0.011 |
0.173 ± 0.023* |
0.471 ± 0.052 |
0.565 ± 0.087* |
Mean ± SD (n=9). *Significant differences between intact and induced ear at P ≤ 0.05 level, ** Significant differences between control and experimental induced ear at P ≤ 0.05 level Table 1: Effects of tested samples on changes in ear weight |
Group |
IL-6 |
IL-10 |
TNF-α |
|||
---|---|---|---|---|---|---|
2 hrs |
6 hrs |
2 hrs |
6 hrs |
2 hrs |
6 hrs |
|
PBS |
0 |
0 |
0 |
0 |
0 |
0 |
LPS |
5,201 ± 626 |
244 ± 18 |
222.3 ± 18.2 |
52.3 ± 9.4 |
12,363 ± 1,017 |
393 ± 22.7 |
Curcumin C3 |
2,515 ± 232* |
111 ± 12* |
101.1 ± 10.1* |
18.1 ± 3.3* |
737 ± 39.9* |
166 ± 15.1* |
Sigma low |
4,486 ± 365 |
201 ± 23 |
179.8 ± 19.3 |
47.2 ± 3.4 |
3.833 ± 474.2* |
277 ± 22.9* |
Sigma high |
3,363 ± 323* |
155 ± 25* |
155.6 ± 13.9* |
37.1 ± 3.5* |
2,061 ± 199.3* |
209 ± 11.8* |
Sample 1 |
5,101 ± 477 |
223 ± 17 |
177.9 ± 20.3 |
39.9 ± 4.2 |
5,636 ± 636.3* |
315 ± 37.8* |
Sample 2 |
4,825 ± 399 |
228 ± 21 |
180.5 ± 18.9 |
35.6 ± 4.1* |
4,282 ± 428.2* |
299 ± 21.5* |
Mean ± SD (n=9). *Significant differences between positive control (LPS) and curcumin treated groups at P ≤ 0.05 level Table 2: Effects of tested samples on cytokine production |
Sample |
AST |
ALT |
ALP |
---|---|---|---|
(IU/L) |
(IU/L) |
(IU/L) |
|
PBS |
72.5 ± 5.2 |
19.1 ± 2.8 |
24.2 ± 2.1 |
CCL4 |
179.7 ± 13.2 |
177.6 ± 19.3 |
178.7 ± 15.7 |
Sample #1 |
73.9* ± 6.0 |
22.2* ± 4.1 |
31.1* ± 4.6 |
Sample #2 |
138.5* ± 9.8 |
51.5* ± 5.8 |
40.3* ± 4.4 |
Sample #3 |
81.5* ± 8.8 |
22.3* ± 4.9 |
27.0* ± 2.2 |
Sample #4 |
111.2* ± 9.9 |
70.2* ± 4.7 |
80.3* ± 8.3 |
Sample #5 |
92.2* ± 4.4 |
23.8* ± 3.3 |
28.6* ± 3.4 |
*Significant difference against CCL4 group at P ≤ 0.05 level Table 3: Effects of tested samples on serum ALT, AST, and ALP |
Sample |
GSH |
MDA |
SOD |
---|---|---|---|
(μmol/mg protein) |
(nmol/ mg protein) |
(U/mg protein) |
|
PBS |
18.1 ± 1.2 |
8.7 ± 0.8 |
58.2 ± 6.1 |
CCL4 |
9.7 ± 0.9 |
77.6 ± 9.1 |
18.7 ± 1.5 |
Sample #1 |
23.0* ± 0.9 |
25.2* ± 9.6 |
40.4* ± 4.5 |
Sample #2 |
12.5 ± 1.7 |
59.4 ± 4.5 |
29.9* ± 2.5 |
Sample #3 |
13.5 ± 1.8 |
21.3* ± 2.1 |
20.1 ± 2.3 |
Sample #4 |
14.3* ± 1.1 |
15.2* ± 1.7 |
23.8 ± 3.3 |
Sample #5 |
10.9 ± 1.6 |
43.2* ± 4.3 |
38.8* ± 4.3 |
*Significant difference against CCL4 group at P ≤ 0.05 level Table 4: Effects of tested samples on level of hepatic enzymes GSH, MDA and SOD |